Are you a physician or nurse?

Yes No

      Clinical Results

      Médico discutindo opções com o paciente durante a consulta

      “The UroLift clinical publication record is flawless. Every patient treated under a clinical protocol appears in at least one peer-reviewed publication. The outcomes from the numerous studies are consistent, demonstrating rapid relief within two weeks and sustained improvement in symptoms, quality of life and urinary flow.”

      - Claus Roehrborn, MD
      Urologist, USA

      *Dr Roehrborn is a paid consultant of Neotract |Teleflex

      Clinical results from over 28 peer-reviewed publications demonstrate that treatment with the UroLift System offers rapid and significant improvements in symptoms, urinary flow and quality of life sustained through five years.1 Compared to medications, the UroLift System has demonstrated a more positive effect on quality of life for patients.1 The UroLift System treatment preserves sexual function and avoids complications typically associated with other BPH procedures.1,2,4,21*

      UroLift System Treatment Delivers:

      Rapid relief and recovery3,4
      Lowest catheter rate of the leading BPH procedures1,3,5,21-23
      No new, sustained erectile or ejaculatory dysfunction2,4,21*
      Proven durability through five years1

      Redefining BPH Treatment

      Most patients living with BPH take prescription medications, but these medications can become a lifelong burden. In a recent men’s health survey, two out of three patients reported frustration with their current BPH prescription.7 These patients have been unwilling to consider a surgical procedure due to the perceived risks and invasive nature of the standard options.

      Now, urologists can offer men the UroLift System treatment—a BPH solution with a low risk profile to improve their patient’s quality of life.4

      What Patients Want: A New Experience

      Patients on BPH Medications Are Not Satisfied

      • 48% of patients on medications do not have a clinically significant improvement in symptoms (< 4 point IPSS improvement)8
      • 5ARI drugs take three to six months for symptom relief9,10
      • Side-effects include headaches, dizziness, asthenia, nasal congestion, loss of libido, ejaculatory dysfunction, and erectile dysfunction2

      Surgery is a Big Step for Patients      

      • Surgery with general anesthesia comes with operative risks: transfusion, significant hematuria2
      • Catheterization for days5
      • Four to six weeks irritative voiding symptoms and recovery2,11-13
      • Risk of permanent complications2
        • Urinary incontinence
        • Sexual dysfunction
        • Urethral stricture

      Even Watchful Waiting Comes with Risks

      • Bladder outlet obstruction may result in irreversible bladder damage if left untreated14,15
      • 87% of men who elect watchful waiting experience a worsening of symptoms over a four year time period16
      • Men who delay TURP with watchful waiting have significantly worse outcomes than those who had TURP sooner17

      Preservation of Sexual Function is Important to BPH Patients

      Erectile dysfunction can contribute to anxiety, depression, loss of self-esteem and diminished quality of life so preserving erectile function significantly impacts quality of life in BPH patients.19 In choosing a BPH treatment, it is important to consider the impact ejaculatory dysfunction and sexual function has on patient satisfaction.

      The UroLift System Treatment: A BPH Procedure Shown Not to Cause New and Lasting Sexual Dysfunction*2,4,21,

      *no new onset, sustained erectile or ejaculatory disfunction

      Tabela de Disfunção Sexual

       

      Five Year Data Demonstrates That Outcomes Are Rapid, Durable and Reproducible

      IPSS Improvement

      Improvement in LUTS, as seen through average reduction in IPSS (International Prostate Symptom Score), has been consistent across the various studies, showing rapid relief within two weeks and sustained effect through five years.1 IPSS improvement at one year is better than seen with medications.2,4 

      Quality of Life Improvement

      Quality of life also improved significantly, with the IPSS QOL and BPH Impact Index maintaining 50% and 52% improvements, respectively at five years, p<0.0001.1

      Flow Rate Improvement

      In addition to improving LUTS, the UroLift System treatment has demonstrated significant average improvement in peak urinary flow rate (Qmax) of 3.5 mL/sec (44%) that was sustained to five years, p<0.0001.1

      Low Retreatment Rate

      The rate of surgical intervention for failure to cure with the UroLift System remains low for a BPH procedure, with approximately 13.6% over five years or about 2-3% per year.1 Over the first postoperative year, no additional surgical intervention was required for bladder neck contracture, bleeding, or stress incontinence in the pivotal study on UroLift System.4

      Tabela de Taxas de Retratamento

       

      Download Bibliography

      View More Publications

      Source Information

      ** Dr Roehrborn is a paid consultant of Neotract | Teleflex

      1. Roehrborn et al. Can J Urol 2017
      2. AUA Guidelines 2003
      3. Shore, Can J Urol 2014
      4. Roehrborn, J Urology 2013
      5. Bachmann, Eur Urol 2014 May
      6. NeoTract US Market Model estimates for 2020, data on file.
      7. Men's health survey, 2018
      8. Wei, et al, J Urol April 2010; AUA 2010 abstract
      9. Pearson, Am Fam Physician 2014
      10. Cindolo, Eur Urol Sep 2015
      11. Miano, Med Sci Mont 2008
      12. Wasson, Perspectives in Nursing 2000
      13. NIH U.S. National Library of Medicine – TURP patient instructions 
      14. Tubaro, Drugs Aging 2003
      15. Mirone, Eur Urol 2007
      16. Djavan, Urology 2004
      17. Flanigan, J Urol 1998
      18. Laumann, Arch Sex Beh April 2006
      19. Carbone, Int J Impot Res 2003
      20. NeoTract Taking Share Survey July 2016 Update; data on file
      21. McVary, J Urol 2016
      22. Mollengarden, Prostate Cancer Prostatic Dis 2018
      23. Gilling, J Urol 2017

      INFORMATION FOR PHYSICIANS ABOUT THE UROLIFT® SYSTEM

      The UroLift System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100 cc in men 50 years or older. The UroLift implants are permanent and can be delivered during an outpatient procedure, relieving prostate obstruction without heating, cutting, destructing, or removing prostate tissue. The UroLift System can be used to treat a broad spectrum of anatomies, including obstructive median lobe.1 It is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction.*2-4 Most common side effects are temporary and can include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence.5 Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Individual results

      may vary. The prostatic urethral lift procedure (using the UroLift System) is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines.

      Contraindicated in men with a prostate volume greater than 100cc or a urinary tract infection.

      Warning: This device contains stainless steel and nitinol, an alloy of nickel and titanium. Persons with allergic reactions to these metals may suffer an allergic reaction to this implant. Prior to implantation, patients should be counseled on the materials contained in the device, as well as potential for allergy/hypersensitivity to these materials.

      Individual results may vary. For full information, please consult the Instructions for Use (IFU)

      *No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T. pivotal study.

      1. Rukstalis, Prostate Cancer and Prostatic Dis 2018
      2. Roehrborn, Can J Urol 2017
      3. AUA BPH Guidelines 2003, 2020
      4. McVary, J Sex Med 2016
      5. Roehrborn, J Urology 2013



      Teleflex, BPH Relief In Sight and UroLift are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. ©2023 Teleflex Incorporated. All rights reserved. Revised: 02/2023. MC-008657 LA EN

      Teleflex Medical Brasil Ltda
      Rua Alexandre Dumas, 2100/132 - Chacara Santo Antonio
      São Paulo/SP - CEP 04717-913